The most effective corticosteroid dose in the treatment of glenohumeral osteoarthritis: Feasibility pilot and protocol for double blinded randomized controlled trial

• Published in: Osteoarthritis and cartilage open Vol. 6; no. 3; p. 100484
• Main Authors: Onks, Cayce, Weaver, Lynn, Latorre, Johan, Silvis, Matthew, Berg, Arthur, Phillips, Shawn, Loeffert, Jayson, French, Cristy, Armstrong, April
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.09.2024; Elsevier
• Subjects: Corticosteroid injection; Feasibility protocol; Glenohumeral osteoarthritis; Glenohumeral osteoarthritis; Corticosteroid injection; Feasibility protocol
• DOI: 10.1016/j.ocarto.2024.100484
• ISSN: 2665-9131

Osteoarthritis affects over 5.4 million people in the United States. A common treatment is to perform intra-articular corticosteroid injections. However, the ideal steroid dose is unknown. This study aimed to pilot a corticosteroid injection protocol for primary glenohumeral OA. We conducted a double blinded randomized feasibility pilot study. Patients with primary osteoarthritis of the glenohumeral joint were recruited and randomized to receive 20 ​mg, 40 ​mg, or 80 ​mg of triamcinolone. The primary outcome was the feasibility of the protocol and change in the Shoulder Pain and Disability Index (SPADI) 6 months following injection. 300 patients were screened for participation with 78 meeting inclusion criteria. 19 subjects completed the study. The most common reason for not participating was concern they would receive a smaller dose than previous injections. There was a 26% dropout rate, with 2 patients undergoing a total shoulder arthroplasty. There was no clinically significant difference (p ​= ​0.090) between the groups at 6-months for the SPADI although all treatment groups showed a reduction of SPADI from baseline at 6 months. There was one adverse event in the 20 ​mg group, with a patient experiencing facial flushing after the injection. We were successful in developing a feasible protocol. In the future excluding those who have received previous injections would be helpful for a higher enrollment rate. This patient concern highlights the need to complete clinical trials to guide medical decisions surrounding corticosteroid administration. NCT03586687.